Werner, Raphael S.
Lauk, Olivia
Tscherry, Georg
Curioni-Fontecedro, Alessandra
Höller, Sylvia
Opitz, Isabelle
Article History
Received: 30 September 2022
Accepted: 30 March 2024
First Online: 15 April 2024
Declarations
:
: Not applicable.
: For the review of clinical records and the publication of this case, a written informed consent was obtained from the patient.
: Olivia Lauk, Georg Tscherry and Sylvia Höller have no competing interests. Raphael S. Werner has the following disclosures: Consultation/advisory role: Bristol-Myers Squibb. Alessandra Curioni-Fontecedro has the following disclosures: Consultation/advisory role: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Merck Sharp and Dohme, Roche/Genentech, Takeda. Talk in a company’s organized public event: Amgen, AstraZeneca, Bristol-Myers Squibb, Foundation Medicine, Medscape, Merck Sharp and Dohme, Roche/Genentech, Takeda. Receipt of grants/research supports: (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp and Dohme, Roche/Genentech. Isabelle Opitz has the following disclosures: Consulting or Advisory Role: AstraZeneca, MSD, BMS, Medtronic, Intuitive (Proctorship). Speaker Bureau: Roche, AstraZeneca. Institutional grants: Roche, Medtronic.